Lexeo Therapeutics, Inc.
LXEONasdaqHealthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | — | — | — | $654,000 |
| Operating income | −$109.3M | −$105.8M | −$68.5M | −$60.5M |
| Net income | −$100.0M | −$98.3M | −$66.4M | −$59.3M |
| Total assets | $268.7M | $146.9M | $139.8M | $97.1M |
| Total liabilities | $22.0M | $30.1M | $26.3M | $25.0M |
| Equity | $246.7M | $116.8M | $113.5M | −$113.0M |
| EPS (diluted) | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
| Shares out. | 33.2M | 26.7M | 26.6M | 1.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −40.5%
- Return on assets
- −37.2%
- Return on capital (ROCE)
- −43.4%
- Liabilities / assets
- 8.2%
- Debt / equity
- 0.09×
- Book value / share
- $7.43
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 8.61safe
- Accruals / assets
- −0.5%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-12Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
- Phase 1Active Not Recruitingreadout ~2028-11Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
- Phase 1/2Active Not Recruitingreadout ~2029-09Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Balyasny Asset Management L.P.Passive (13G)May 15, 2026
- Paradigm Biocapital Advisors LpPassive (13G)May 15, 2026
- Suvretta Capital Management, LlcPassive (13G)Apr 13, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Citadel Advisors LlcPassive (13G)Feb 17, 2026
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Feb 13, 2026
- Affinity Asset Advisors, LlcPassive (13G)Jan 29, 2026
- Blackrock, Inc.Passive (13G)Jan 21, 2026
- Janus Henderson Group PlcPassive (13G)Dec 8, 2025
- Longitude Capital Partners Iv, LlcPassive (13G)Nov 14, 2025
- Vestal Point Capital, LpPassive (13G)Nov 14, 2025
- Integrated Core Strategies (Us) LlcPassive (13G)Nov 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Otero Jose ManuelOfficer — Chief Operating Officer | Mar 13, 2026 | Grant | 5,930 | $2.64 |
| Otero Jose ManuelOfficer — Chief Operating Officer | Feb 18, 2026 | Sell | 3,016 | $6.40 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 13.2M | 18.8 | +1.1% |
| Apr 30, 2026 | 13.1M | 18.9 | +3.7% |
| Apr 15, 2026 | 12.6M | 9.9 | +0.9% |
| Mar 31, 2026 | 12.5M | 14.1 | +5.9% |
| Mar 13, 2026 | 11.8M | 11.4 | +6.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Other material eventMay 11, 2026
- Director / officer changeApr 30, 2026
- Results of operations · Other material eventMar 30, 2026
- Director / officer changeFeb 5, 2026
- Director / officer changeJan 27, 2026
- Regulation FD disclosure · Other material eventJan 12, 2026
- Results of operationsNov 5, 2025
- Entered a material agreement · Results of operations · Unregistered equity sale · Other material eventOct 17, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.